+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Treatment of CNS tumors with metalloprotease inhibitors



Treatment of CNS tumors with metalloprotease inhibitors



Official Gazette of the United States Patent & Trademark Office Patents 1231(3), Feb 15



The present invention relates to genes and their encoded proteins which regulate neurite growth and the diagnostic and therapeutic use of such proteins (termed herein neurite growth regulatory factors). The proteins of the present invention include central nervous system myelin associated proteins and metalloproteases associated with glioblastoma cells and other malignant tumors which can metastasize to the brain. The metalloproteases of the invention have value in the treatment of nerve damage and of degenerative disorders of the nervous system. The present invention is also directed to inhibitors of the metalloproteases. Such inhibitors in combination with the CNS myelin associated inhibitory proteins can be used in the treatment of malignant tumors.

(PDF emailed within 1 workday: $29.90)

Accession: 035980358

Download citation: RISBibTeXText


Related references

The new class of drugs-- metalloprotease inhibitors -- in the treatment of heart failure. Klinicheskaia Meditsina 82(5): 7-15, 2004

Treatment of central nervous system inflammatory disease with matrix metalloprotease inhibitors. Official Gazette of the United States Patent & Trademark Office Patents 1188(1): 442, July 2, 1996

Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD). Bioorganic & Medicinal Chemistry Letters 22(1): 138-143, 2012

Human tumors retain sensitivity to AG3340, a selective metalloprotease inhibitor, after extended treatment and serial passage in vivo. Proceedings of the American Association for Cancer Research Annual Meeting 40: 709, March, 1999

Magnetic resonance imaging detects early changes in microvascular permeability in xenograft tumors after treatment with the matrix metalloprotease inhibitor Prinomastat. Technology in Cancer Research & Treatment 3(4): 377-382, 2004

Silanediol metalloprotease inhibitors Synthesis and evaluation of four ACE inhibitors. Abstracts of Papers American Chemical Society 225(1-2): MEDI 176, 2003

Silicon-based metalloprotease inhibitors: synthesis and evaluation of silanol and silanediol peptide analogues as inhibitors of angiotensin-converting enzyme. Journal of the American Chemical Society 124(25): 7363-7375, 2002

Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. Journal of Medicinal Chemistry 40(11): 1570-1577, 1997

Dual metalloprotease inhibitors. 6. Incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors. Journal of Medicinal Chemistry 39(2): 494-502, 1996

Use of pituitary inhibitors in the treatment of malignant tumors, particularly breast tumors. Therapie 12(4): 583-600, 1957

Metalloprotease inhibitors. Official Gazette of the United States Patent & Trademark Office Patents 1254(3), Jan 15, 2002

Metalloprotease inhibitors. Official Gazette of the United States Patent & Trademark Office Patents 1266(4), Jan 28, 2003

Metalloprotease inhibitors. Official Gazette of the United States Patent & Trademark Office Patents 1279(1), Feb 3, 2004

Matrix metalloprotease inhibitors. Official Gazette of the United States Patent & Trademark Office Patents 1255(4), Feb 26, 2002

Lactam metalloprotease inhibitors. Official Gazette of the United States Patent & Trademark Office Patents 1273(4), Aug 26, 2003